CoChat

Adrenergic Mediation of Hypoglycemia-Associated Autonomic Failure

Open access

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We tested the hypothesis that adrenergic activation, cholinergic activation, or both, mediate the effect of recent antecedent hypoglycemia to reduce the sympathoadrenal response to subsequent hypoglycemia, the key feature of hypoglycemia-associated autonomic failure in diabetes, in humans. RESEARCH DESIGN AND METHODS: Seventeen healthy adults were studied on 2 consecutive days on three occasions. Day 1 involved hyperinsulinemic euglycemic (90 mg/dL × 1 h), then hypoglycemic (54 mg/dL × 2 h) clamps, in the morning and afternoon on all three occasions with 1) saline infusion, 2) adrenergic blockade with the nonselective α-adrenergic and β-adrenergic antagonists phentolamine and propranolol, or 3) adrenergic blockade plus cholinergic blockade with the muscarinic cholinergic antagonist atropine in random sequence. Day 2 involved similar morning euglycemic and hypoglycemic clamps, with saline infusion, on all three occasions. RESULTS: Compared with the responses to hypoglycemia during saline infusion on day 1, the plasma epinephrine and norepinephrine responses to hypoglycemia were reduced on day 2 (351 ± 13 vs. 214 ± 22 pg/mL for epinephrine and 252 ± 4 vs. 226 ± 7 pg/mL for norepinephrine during the last hour; both P < 0.0001). However, the plasma epinephrine and norepinephrine responses to hypoglycemia were not reduced on day 2 when adrenergic or adrenergic plus cholinergic blockade was produced during hypoglycemia on day 1. CONCLUSIONS: Adrenergic blockade prevents the effect of hypoglycemia to reduce the plasma catecholamine responses to subsequent hypoglycemia. Thus, adrenergic activation mediates the effect of recent antecedent hypoglycemia to reduce the sympathoadrenal response to subsequent hypoglycemia, the key feature of hypoglycemia-associated autonomic failure in diabetes, in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db10-1374

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Mean (SEs within the symbols) plasma glucose concentrations are shown during morning and afternoon hyperinsulinemic euglycemic and hypoglycemic clamps with intravenous infusions of saline (○), phentolamine plus propranolol (PTL + PRP, □) or phentolamine plus propranolol with injection of atropine (PTL + PRP + Atropine, △) on day 1 and during morning hyperinsulinemic euglycemic and hypoglycemic clamps with intravenous infusion of saline on day 2 after saline (●), PTL + PRP (■) or PTL + PRP + Atropine (▲) on day 1 on three separate occasions.
FIG. 1. Mean (SEs within the symbols) plasma glucose concentrations are shown during morning and afternoon hyperinsulinemic euglycemic and hypoglycemic clamps with intravenous infusions of saline (○), phentolamine plus propranolol (PTL + PRP, □) or phentolamine plus propranolol with injection of atropine (PTL + PRP + Atropine, △) on day 1 and during morning hyperinsulinemic euglycemic and hypoglycemic clamps with intravenous infusion of saline on day 2 after saline (●), PTL + PRP (■) or PTL + PRP + Atropine (▲) on day 1 on three separate occasions.CC BY-NC-ND · PubMed Central
FIG. 2. Mean (± SE) plasma epinephrine, norepinephrine, and pancreatic polypeptide concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps with intravenous infusions of saline (○), phentolamine plus propranolol (PTL + PRP, □), or phentolamine plus propranolol with atropine (△) on day 1. The P values represent comparisons with the values during saline infusion (both P < 0.0001) for epinephrine and norepinephrine and comparisons with values during phentolamine plus propranolol with atropine (P < 0.0001) for pancreatic polypeptide.
FIG. 2. Mean (± SE) plasma epinephrine, norepinephrine, and pancreatic polypeptide concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps with intravenous infusions of saline (○), phentolamine plus propranolol (PTL + PRP, □), or phentolamine plus propranolol with atropine (△) on day 1. The P values represent comparisons with the values during saline infusion (both P < 0.0001) for epinephrine and norepinephrine and comparisons with values during phentolamine plus propranolol with atropine (P < 0.0001) for pancreatic polypeptide.CC BY-NC-ND · PubMed Central
FIG. 3. Mean (± SE) plasma insulin, glucagon, growth hormone, and cortisol concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps with intravenous infusions of saline (○), phentolamine plus propranolol (□), or phentolamine plus propranolol with atropine (△) on day 1. The P values represent comparisons with the values during saline, both P < 0.0001 for insulin, growth hormone, and cortisol.
FIG. 3. Mean (± SE) plasma insulin, glucagon, growth hormone, and cortisol concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps with intravenous infusions of saline (○), phentolamine plus propranolol (□), or phentolamine plus propranolol with atropine (△) on day 1. The P values represent comparisons with the values during saline, both P < 0.0001 for insulin, growth hormone, and cortisol.CC BY-NC-ND · PubMed Central
FIG. 4. Mean (± SE) plasma epinephrine, norepinephrine, and pancreatic polypeptide concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps on day 1 with saline infusion (○) and on day 2 after saline (●), phentolamine plus propranolol (PTL + PRP, ■), or phentolamine plus propranolol with atropine (PTL + PRP + Atropine, ▲) during the clamps on day 1. The P values represent comparisons with the values during saline infusion on day 1 (○), P < 0.0001 for epinephrine and norepinephrine on day 2 (●), and P < 0.0001 for pancreatic polypeptide under all three conditions on day 2 (●, ■, and ▲).
FIG. 4. Mean (± SE) plasma epinephrine, norepinephrine, and pancreatic polypeptide concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps on day 1 with saline infusion (○) and on day 2 after saline (●), phentolamine plus propranolol (PTL + PRP, ■), or phentolamine plus propranolol with atropine (PTL + PRP + Atropine, ▲) during the clamps on day 1. The P values represent comparisons with the values during saline infusion on day 1 (○), P < 0.0001 for epinephrine and norepinephrine on day 2 (●), and P < 0.0001 for pancreatic polypeptide under all three conditions on day 2 (●, ■, and ▲).CC BY-NC-ND · PubMed Central
FIG. 5. Mean (± SE) plasma insulin, glucagon, growth hormone, and cortisol concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps on day 1 with saline infusion (○) and on day 2 after saline (●), phentolamine plus propranolol (■), or phentolamine plus propranolol with atropine (▲) during the clamps on day 1. The P values represent comparisons with the values during saline on day 1 (○); see text for details.
FIG. 5. Mean (± SE) plasma insulin, glucagon, growth hormone, and cortisol concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps on day 1 with saline infusion (○) and on day 2 after saline (●), phentolamine plus propranolol (■), or phentolamine plus propranolol with atropine (▲) during the clamps on day 1. The P values represent comparisons with the values during saline on day 1 (○); see text for details.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

Metadata

Authors
Ramanathan, R., & Cryer, P. E.
Affiliations
Washington University in St. Louis (US)
Corresponding author
Cryer, Philip E.
Venue
Diabetes
Published
2011-01-21
Volume
60
Issue
2
Pages
602-606
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2156076680
Cited by
42
References
22
Citations by year
2026: 3 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 6 · 2012: 3
FWCI
3.14
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • Bristol-Myers Squibb
  • AstraZeneca
  • Novo Nordisk
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, R37-DK27085)
  • National Center for Research Resources (UL1-RR-24992, UL1RR024992)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Syncope and Autonomic Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
hypoglycemia-associated autonomic failure, adrenergic blockade, sympathoadrenal response, catecholamines, epinephrine, norepinephrine, phentolamine, propranolol, atropine, cholinergic blockade, hyperinsulinemic hypoglycemic clamp
MeSH terms
Adrenergic alpha-Antagonists, Adrenergic beta-Antagonists, Adult, Analysis of Variance, Atropine, Autonomic Nervous System, Blood Glucose, Epinephrine, Female, Humans, Hypoglycemia, Insulin, Male, Norepinephrine, Phentolamine, Propranolol, Glucose Clamp Technique, Muscarinic Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.